Conjugate Vaccines Market, By Application (Brain tumor, Blood, Breast, Ovarian, Lung Cancer), Technology (Cleavable Linker, Non Cleavable Linker), and By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East and the Rest of the World) – Market Size & Forecasting to 2028

The Global Conjugate Vaccines Market size is predicted to succeed in USD 10.14 billion by 2028. It's projected to grow at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer and the growing geriatric population are likely to drive the marketplace for conjugate vaccines. Furthermore, major technological advancements also are contributing to drive expansion. Consistent with the World Health Organization (WHO), the number of individuals aged 65 years and above is projected to succeed 16% of the entire population by 2050 from 7% in 2000. Aging has become a considerable risk factor for varied diseases including cancer. Hence, the growing geriatric population is predicted to drive the growth of the market over the forecast period.

Until 2018, four conjugate vaccines were available within the market, namely Adcetris, Kadcyla, Besponsa, and Mylotarg. Owing to appropriate targeting and improved technology, conjugate vaccines are gaining tons of attention from both small and major pharmaceutical companies. Currently, there are approximately 50 conjugate vaccines in clinical trials and it's been projected that in the forecast period, three to four conjugate vaccines are going to be commercialized covering the areas of Refractory Hodgkin Lymphoma, Glioblastoma, Small Cell Carcinoma, Carcinoma, and Ovarian Cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma. Seattle Genetics and Roche are leading the conjugate vaccines market in terms of market share. Until 2017 only two conjugate vaccines were commercially available - Adcetris by Seattle Genetics, and Kadcyla by Roche. Recently, two more Pfizer products were approved to be marketed for Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Hence, it's been estimated that over the forecast period, Pfizer is anticipated to realize a big market share.

Key Insights - Conjugate Vaccines Market:

  • Breast cancer was the most important segment in 2019 and is probably going to witness a big growth over the forecast period owing to the factors such as the availability of Kadcyla and high prevalence of carcinoma
  • Cleavable linkers are predicted to witness the fastest growth over the forecast period because most products currently in the development pipeline are cleavable linkers. Additionally, in 2017, two new products – Besponsa and Mylotarg – were approved within the market
  • In 2019, North America was the most important revenue-generating region within the conjugate vaccines market. It is the foremost among well-established regions in terms of patient awareness and usage of conjugate vaccines, and makes up most of the prevailing market
  • The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Drug Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
  • Market players are adopting various strategies – like introducing technologically advanced products, collaborations, and geographic expansions – to increase their market share. For example, Seattle Genetics collaborated with Takeda for developing Brentuximab Vedotin (Adcetris) for refractory/relapsed Hodgkin Lymphoma.

The Conjugate Vaccines market segmentation is based on application, technology, and region.

Application Outlook:

Conjugate vaccines combine the sensitive and unique targeting abilities of antibodies which allows sensitive discrimination between cancer tissues and healthy tissues, with the cell-killing ability of cytotoxic drugs. All four conjugate vaccines available within the market are approved for the treatment of cancer.

Based on the application, the market is categorized into blood cancer carcinoma, ovarian cancer, carcinoma, and brain tumor. Carcinoma was the most revenue-generating segment in 2017 due to the presence of factors such as the high prevalence of carcinoma on a global scale, and commercial availability of Kadcyla in most of the key regions.

Rising prevalence of cancer is one of the main drivers accelerating the conjugate vaccines market. Consistent with the World Health Organization (WHO), in 2018 the foremost common sorts of cancer were carcinoma with 2.09 million cases, colorectal cancer with 1.80 million cases, prostatic adenocarcinoma with 1.28 million cases, and stomach cancer with 1.03 million cases.

Technology Outlook:

Based on technology, the market is bifurcated into cleavable and non-cleavable linkers. These two are the foremost predominant technologies sought to link cytotoxic anticancer agents’ payloads. For example, two of the bestselling conjugate vaccines – Adcetris and Kadcyla – contains cleavable and non-cleavable linkers.

It has been estimated that cleavable linkers will witness the fastest growth over the forecast period due to factors like the wide usage of those linkers and maximum number of products within the pipeline. Furthermore, in 2017, two new Pfizer products – Besponsa and Mylotarg – were approved for usage in developed regions, and both contain cleavable linkers.

Production of suitable chemical linkers between the antibody and the medicine is one of the greatest challenges in manufacturing effective and safe conjugate vaccines. The synthesis of linker chemistry is comparatively complex and various features must be balanced to ensure efficacy as eventually, the sort of linker getting used forms the discharge profile of the cytotoxin.

Regional Outlook:

In 2019, North America was the most revenue-generating region, followed by Europe. The main factor attributing for this and their continued dominance includes the presence of serious market players, like Seattle Genetics, Roche, Pfizer, and AbbVie. North America is the most well-established market in terms of the usage of conjugate vaccines, including well-established healthcare infrastructure and patient awareness.

North America is projected to witness the fastest growth over the forecast period as most of the conjugate vaccines currently in pipeline are being developed in the U.S. Also, the U.S. Food and Drug Administration (FDA) is one among the primary regulatory bodies to approve conjugate vaccines in U.S. Hence, these factors are likely to spruce up market growth within the region over the forecast period.

Competitive Landscape

Key market players are Seattle Genetics, Inc.; Takeda Pharmaceutical Company Limited; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; and AbbVie Inc. The businesses are adopting different marketing strategies like geographic expansion, collaborations, and R&D activities to extend their market share.

For instance, Seattle Genetics, Inc. recently collaborated with Takeda Pharmaceutical Company Limited to develop and commercialize Adcetris on a worldwide scale. Under this collaboration, Seattle Genetics retained commercial rights for Adcetris in U.S. and Canada, and Takeda has commercial rights within the remainder of the planet. Furthermore, Seattle Genetics and Takeda also are collaborating for developing Brentuximab Bedotin (Adcetris) for relapsed/refractory Hodgkin Lymphoma.

Key Developments in Conjugate Vaccines Market:

  • In May 2017, Union Minister for Health and Family Welfare J P Nadda launched Pneumococcal Conjugate Vaccine (PCV) against Pneumonia under the Universal Immunization Programme (UIP).
  • In November 2019, Pakistan became the first country in the world to introduce typhoid conjugate vaccine (TCV) into its routine immunisation program through a campaign in Sindh.

What Does This Report Provide?

This report provides a detailed understanding of the global Conjugate Vaccines market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Market Segmentation:

By Application

  • Brain tumor
  • Blood
    • Leukemia
    • Lymphoma
  • Breast
  • Ovarian
  • Lung

By Technology

  • Cleavable Linker
  • Non Cleavable Linker

By Region:

  • North America
    • By Country (US, Canada, Mexico)
    • By Application
    • By Technology
  • Western Europe
    • By Country (Germany, UK, France, Italy, Spain, Rest of Europe)
    • By Application
    • By Technology
  • Eastern Europe
    • By Country (Russia, Turkey)
    • By Application
    • By Technology
  • Asia Pacific
    • By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
    • By Application
    • By Technology
  • Middle East
    • By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East and Africa)
    • By Application
    • By Technology
  • Rest of the World
    • By Region (South America, Africa)
    • By Application
    • By Technology

Reasons to Buy This Report:

  • Market size estimation of the Conjugate Vaccines market on a regional and global basis
  • Unique research Usage for market size estimation and forecast
  • Profiling of major companies operating in the market with key developments
  • Broad scope to cover all the possible segments helping every stakeholder in the market

Customization:

We provide customization of the study to meet specific requirements:

  • By Segment
  • By Sub-segment
  • By Region/Country

For more information, contact: sales@quincemarketinsights.com